NCT00624325View on ClinicalTrials.gov

Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

December 31, 2010

Conditions
Chronic Hepatitis C
Interventions
DRUG

interferon alfa-2b

12 MU daily continuously subcutaneous

DRUG

interferon alfa-2b

9 MU daily continuously subcutaneous

DRUG

interferon alfa-2b

6 MU daily continuously subcutaneous

Trial Locations (1)

3015 GD

Erasmus University Medical Center, Rotterdam

Sponsors
All Listed Sponsors
lead

Foundation for Liver Research

OTHER